��������

Christopher Zwolinski is an accomplished Scientist II at BridgeBio, focusing on upstream AAV gene therapy process development and tech transfer for GMP manufacturing. With experience in various bioreactor scales and significant roles in other prestigious organizations, including The Duke Human Vaccine Institute and Seqirus, Christopher has a strong background in upstream process development and vaccine production. Previous positions involved leading engineering initiatives, facilitating viral pilot plant operations, and participating in facility start-ups. Christopher holds a Master’s and Bachelor’s degree in Biomedical Engineering from Rensselaer Polytechnic Institute, where research contributions led to publications in leading scientific journals.